Revenue
2025
Drugs Made In America Acquisition II Corp. (DMII)
Price$10.17Cached quote
Net income
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | |
|---|---|
| Revenue | $0 |
| Operating expenses | $488,385 |
| Operating income | −$488,385 |
| EBITDA | −$1.3M |
| Net income | $4.2M |
| Basic EPSper basic share | $0.16 |
| Diluted EPSper diluted share | $0.15 |
Owners
Reported shareholders
≈48.97%of listed shares
Stockwell Lynn6.71M shares · Sep 26, 2025
View holders
| Holder | % owned |
|---|---|
Stockwell Lynn | ≈48.97%6.71M shares |
Drugs Made In America Acquisition II LLC | ≈48.97%6.71M shares |
Karpus Management, Inc. | 20.35%2.79M shares |
MMCAP International Inc. SPC | 19.71%2.7M shares |
Magnetar Financial LLC | 19.71%2.7M shares |
GLAZER CAPITAL, LLC | 17.10%2.34M shares |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 16.36%2.24M shares |
MILLENNIUM MANAGEMENT LLC | 14.55%1.99M shares |
Hudson Bay Capital Management LP | 14.37%1.97M shares |
WOLVERINE ASSET MANAGEMENT LLC | 13.54%1.86M shares |
Polar Asset Management Partners Inc. | 10.95%1.5M shares |
TENOR CAPITAL MANAGEMENT Co., L.P. | 10.95%1.5M shares |
D. E. Shaw & Co., Inc. | 10.77%1.48M shares |
AQR Arbitrage LLC | 8.26%1.13M shares |
ARISTEIA CAPITAL, L.L.C. | 8.03%1.1M shares |
Crossingbridge Advisors, LLC | 8.03%1.1M shares |
First Trust Capital Management L.P. | 7.79%1.07M shares |
OMERS ADMINISTRATION Corp | 7.30%1M shares |
Davidson Kempner Capital Management LP | 7.30%1M shares |
PICTON MAHONEY ASSET MANAGEMENT | 6.48%888K shares |
Percentages use 13.7M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 26, 2025Form 4 | Stockwell LynnCEO and Exe. Chair of Board | SellOrdinary shares · indirect | 7.97M | — | — | 6.71M |
| Sep 26, 2025Form 4 | Stockwell LynnCEO and Exe. Chair of Board | BuyOrdinary shares · indirect | 700.0K | — | — | 15.07M |
| Sep 26, 2025Form 4 | Stockwell LynnCEO and Exe. Chair of Board | BuyRights to receive ordinary shares · derivative · indirect | 700.0K | — | — | 700.0K |
| Sep 26, 2025Form 4 | Drugs Made In America Acquisition II LLCTenPercentOwner | SellOrdinary shares | 7.97M | — | — | 6.71M |
| Sep 26, 2025Form 4 | Drugs Made In America Acquisition II LLCTenPercentOwner | BuyOrdinary shares | 700.0K | — | — | 15.07M |